Focal segmental glomerulosclerosis research hub
8 indexed studies · 7 currently recruiting
- recruitingPhase III
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis
This clinical trial is testing a new medicine called DMX-200 for focal segmental glomerulosclerosis (FSGS), a rare kidney condition. Researchers want to see if adding DMX-200 to standard blood pressure medication helps protect kidney filters, reduces protein leaking into the urine, and slows down kidney damage better than a dummy pill.
United Kingdom · England · Scotland - recruitingTherapeutic exploratory (Phase II)
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis.
This study is looking into a new medicine, BI 764198, for people with a kidney condition called focal segmental glomerulosclerosis. We want to see if it helps reduce protein in the urine and if it's safe to use, compared to a dummy pill.
Belgium · Spain · Germany - recruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
United States · Argentina · Australia - recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This study is looking at new medicines (frexalimab, brivekimig, or rilzabrutinib) for kidney conditions called Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD). It aims to see if these medicines are safe and can help improve kidney function compared to a dummy drug.
United States · Argentina · Australia - not yet recruiting
Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
This study looks at people with a specific kidney problem called nephrotic syndrome, linked to a gene called APOL1. Researchers want to understand what helps patients get better and if steroid medicines are useful. It's an observational study, meaning no new treatments are given.
France - recruitingPHASE2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
This study is looking at a new medicine called sparsentan for children aged 1 to 17 with certain kidney conditions like FSGS, MCD, IgAN, IgAV, and Alport Syndrome. It will check if the medicine is safe, works well, and how the body handles it over two years.
United States · Germany · Italy - recruiting
National Registry of Rare Kidney Diseases
This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.
United Kingdom - active not recruitingPHASE2
Atrasentan in Patients With Proteinuric Glomerular Diseases
This study looks at a new medicine called atrasentan for people with certain kidney diseases. It aims to see if atrasentan can help reduce protein in the urine and protect kidney function. Different groups of patients with kidney conditions like IgA nephropathy and diabetic kidney disease are being included.
United States · Australia · Italy